Datasets:
timotheeplanes
/
doping

Dataset card Data Studio Files
xet
 Community
1
text
stringlengths
1
17.8k
[Comment to 4.8.14.4: For example, if an attempt to test an Athlete in a Registered Testing Pool during a 60- minute time slot is unsuccessful due to a third party filing the wrong information, or failing to update previously -filed information where the details have subsequently changed, the Athlete will sti ll be liable for a Whereabouts Failure .
This must be the case because if an Athlete is able to blame their third part y for being unavailable or inaccessible for Testing at a location specified by their third party , then they will be able to avoid accountability for their whereabouts for Testing.
Of course, the third party has the same interest as the Athlete in ensuring the accuracy of the Whereabouts Filing and avoiding any Whereabouts Failures on the part of the Athlete.
If the third party is a team official filing the wrong information in relation to the Team Activity or failing to update previously filed information where the details of the Team Activity have subsequently changed, then the team may be separately liable for sanction under the applicable rules of the International ISTI – Effective 1 January 2023 Page 40 of 92 Federation or National Anti -Doping Organization for such failure.
If the Athlete/s is/are in a Testing pool, then the Athlete/s will be subject to the applicable consequences under the rules of the International Federation or National Anti-Doping Organization. ]
4.9 Coordinating with O ther Anti-Doping Organizations 4.9.1 Anti-Doping Organizations shall coordinate their Testing efforts with the efforts of other Anti-Doping Organizations with overlapping Testing Authority , in order to maximize the effectiveness of those combined efforts, to avoid unnecessarily repetitive Testing of particular Athletes and to ensure Athletes compet ing at International Events are suitably tested in advance.
In particular , Anti-Doping Organizations shall: a)Consult with other relevant Anti-Do ping Organizations in order to coordinate Testing activities (including Athlete whereabouts pool selection and Test Distribution Plans, whic h may include Out-of-Co mpetition Tes ting in the lead up to a major Event) and to avoid duplication.
Clear agreement on roles and responsibilities for Event Tes ting shall be agreed in advance in accordance with Code Article 5.3.
Where such agreement is not possible, WADA will resolve the matter i n accordance with the principles set out at Annex H - Ev ent Testing;b)Within twenty-on e (21) days of Sample c ollection, enter the Doping Control form into ADAMS for all Samples c ollectedc)Share information on whereabouts requirements on Athletes where there is overlapping Testing Authority via ADAMSd)Share information on Athlete Biological Passport programs where there is overlapping Testing Authority via ADAMS; ande)Share intelligence on Athletes where there is overlapping Testing Authority 4.9.2 Anti-Doping Organizations may contract other Anti-Doping Organizations or Delegated Third Parties to act as a Doping Control Coordinator or Sample Collection Authority on their behalf.
In the terms of the contract, the commissioning Anti-Doping Organization (which, for these purposes, is the Testing Authority ) may specify how any discretion afforded to a Sample Collection Authority under the International Standard for Testing and Investigations is to be exercised by the Sample Collection Authority when collecting Samples on its behalf.
[Comment to 4.9.2: For example, the International Standard for Testing and Investigations confers discretion as to the criteria to be used to validate the identity of the Athlete (Article 5.3.4), as to the circumstances in which delayed reporting to the Doping Control Station may be permitted (Article 5.4.4), as to who may be present during the Sample Collection Session (Article 6.3.3), as to the criteria to be used to ensure that each Sample collected is stored in a manner that protects its integrity, identity and security prior to transport from the Doping Control Station (Article 8.3.1), and as to the guidelines to be followed by the DCO in determining whether exceptional circumstances exist that mean a Sample Collection Session should be abandoned without collecting a Sample with a Suitable Specific Gravity for Analysis (Article F.4.5) and share information/intelligence obtained (Article 11).]
ISTI – Effective 1 January 2023 Page 41 of 92 4.9.3 Anti-Doping Organizations should consult and coordinate with each other, with WADA , and with law enforcement and other relevant authorities, in obtaining, developing and sharing information and intelligence that can be useful in informing Test distribution planning, in accordance with Article 11 .
5.0 Notification of Athletes 5.1 Objective The objective is to ensure that an Athlete who has been selected for Testing is properly notified with no advance notice of Sample collection as outlined in Articles 5.3.1 and 5.4.1, that the rights of the Athlete are maintained, that there are no opportunities to manipulate the Sample to be provided, and that the notification is documented.
5.2 General Notification of Athletes starts when the Sample Collection Authority initiates the notification of the selected Athlete and ends when the Athlete arrives at the Doping Control Station or when the Athlete’s possible Failure to Comply occur s. The main activities are: a) Appointment of DCOs , Chaperones and other Sample Collection Personnel sufficient to ensure No Advance Notice Testing and continuous observation of Athletes notified of their selection to provide a Sample ; b) Locating the Athlete and confirming their identity; c) Informing the Athlete that they have been selected to provide a Sample and of their rights and responsibilities; d) Continuously chaperoning the Athlete from the time of notification to the arrival at the designated Doping Control Station; and e) Documenting the notification, or notification attempt.
5.3 Requirements Prior to Notification of Athletes 5.3.1 No Advance Notice Testing shall be the method for Sample collection save in exceptional and justifiable circumstances.
The Athlete shall be the first Person notified that they have been selected for Sample collection, except where prior contact with a third party is required as specified in Article 5.3.7.
In order to ensure that Testing is conducted on a No Advance Notice Testing basis, the Testing Authority (and the Sample Collection Authority , if different) shall ensure that Athlete selection decisions are only disclosed in advance of Testing to those who strictly need to know in order for such Testing to be conducted.
Any notification to a third party shall be conducted in a secure and confi dential manner so that there is no risk that the Athlete will receive any advance notice of their selection for Sample collection.
For In-Competition Testing , such notification shall occur at the end of the Competition in which the Athlete is competing.
[Comment to 5.3.1: Every effort should be made to ensure Event Venue or training venue staff are not aware that Testing may take place in advance.
It is not justifiable ISTI – Effective 1 January 2023 Page 42 of 92 for a National Federation or other body to insist that it be given advance notice of Testing of Athletes under its authority so that it can have a representative present at such Testing.]
5.3.2 To conduct or assist with t he Sample Collection Sessions , the Sample Collection Authority shall appoint and authorize Sample Collection Personnel who have been trained for their assigned responsibilities, who do not have a conflict of interest in the outcome of the Sample collection, and who are not Minors .
5.3.3 Sample Collection Personnel shall have official documentation, provided by the Sample Collection Authority , evidencing their authority to collect a Sample from the Athlete, such as an authorization letter from the Testing Authority .
DCOs shall also carry complementary identification which includes their name and photograph (i.e., identification card f rom the Sample Collection Authority , driver’s license, health card, passport or similar valid identification) and the expiry date of the identification.
5.3.4 The Testing Authority or otherwise the Sample Collection Authority shall establish criteria to validate the identity of an Athlete selected to provide a Sample.
This ensures the selected Athlete is the Athlete who is notified.
If the Athlete is not readily identifiable, a third party may be asked to identify them and the details of such identification documented.
5.3.5 The Sample Collection Authority , DCO or Chaperone, as applicable, shall establish the location of the selected Athlete and plan the approach and timing of notification, taking into consideration the specific circumstances of the sport/ Competition /training session/etc.
and the situation in question.
5.3.6 The Sample Collection Authority , DCO or Chaperone, as applicable, shall document Athlet e notification attempt(s) and outcome(s).
5.3.7 The Sample Collection Authority , DCO or Chaperone, as applicable, shall consider whether a third party is required to be notified prior to notification of the Athlete; in the following situations: a) Where required by an Athlete’s impairment (as provided for in Annex A - Modifications for Athletes with Impairments); b) Where the Athlete is a Minor (as provided for in Annex B - Modifications for Athletes who are Minors ); c) Where an interpreter is required and available for the notificat ion; d) Where required to assist Sample Collection Personnel to identify the Athlete(s) to be tested and to notify such Athlete(s) that they are required to provide a Sample.
[Comment to 5.3.7: It is permissible to notify a third party that Testing of Minors or Athletes with impairments will be conducted.
However, there is no requirement to notify any third party (e.g., a team doctor) of the Doping Control mission where such assistance is not needed.
Should a third party be required to be notified prior to notification, the third party should be accompanied by the DCO or Chaperone to notify the Athlete.]
ISTI – Effective 1 January 2023 Page 43 of 92 5.4 Requirements for Notification of Athletes 5.4.1 When initial contact is made, the Sample Collection Authority , DCO or Chaperone, as applicable, shall ensure that the Athlete and/or a third party (if required in accordance with Article 5.3.7) is informed: a) That the Athlete is required to undergo a Sample collection; b) Of the authority under which the Sample collection is to be conducted; c) Of the type of Sample collection and any conditions that need to be adhered to prior to the Sample collection; d) Of the Athlete’s rights, including the right to: (i) Have a representative and, if available, an interpreter accompany them, in accordance with Article 6.3.3(a); (ii) Ask for a dditional information about the Sample collection process; (iii) Request a delay in reporting to the Doping Control Station for valid reasons in accordance with Article 5.4.4; and (iv) Request modifications as provided for in Annex A - Modifications for Athletes with Impairments.
e) Of the Athlete’s responsibilities, including the requirement to: (i) Remain within continuous observation of the DCO /Chaperone at all times from the point initial contact is made by the DCO /Chaperone until the completion of the Sample collection procedure; (ii) Produce identification in accordance with Article 5.3.4; (iii) Comply with Sample collection procedures (and the Athlete should be advised of the possible Consequences of a Failure to Comply ); and (iv) Report immediately for Sample collection, unless there are valid reasons for a delay, as determined in accordance with Article 5.4.4. f) Of the location of the Doping Control Station; g) That should the Athlete choose to consume food or fluids prior to providing a Samp le, they do so at their own risk; h) Not to hydrate excessively, since this may delay the production of a suitable Sample; and i) That any urine Sample provided by the Athlete to the Sample Collection Personnel shall be the first urine passed by the Athlete subs equent to notification.
5.4.2 When contact is made, the DCO /Chaperone shall : ISTI – Effective 1 January 2023 Page 44 of 92 a) From the time of such contact until the Athlete leaves the Doping Control Station at the end of their Sample Collection Session, keep the Athlete under observation at all times; b) Identify themselves to the Athlete using the documentation referred to in Article 5.3.3; and c) Confirm the Athlete’s identity as per the criteria established in Article 5.3.4.
Confirmation of the Athlete’s identity by any other method, or failure to confirm the identity of the Athlete , shall be documented and reported to the Testing Authority .
In cases where the Athlete’s identity cannot be confirmed as per the criteria established in Article 5.3.4, the Testing Authority shall decide whether it is appropriate to follow up in accordance with Annex A - Review of a Possible Failure to Comply of the International Standard for Results Management .
5.4.3 The DCO /Chaperone shall have the Athlete sign an appropriate form to acknowledge and accept the notification.
If the Athlete refuses to sign that they have been notified, or evades the notification, the DCO /Chaperone shall, if possible, inform the Athlete of the Consequences of a Failure to Compl y, and the Chaperone (if not the DCO ) shall immediately report all relevant facts to the DCO .
When possible, the DCO shall continue to collect a Sample .
The DCO shall document the facts in a detailed report and report the circumstances to the Testing Autho rity.
The Testing Authority shall follow the steps prescribed in Annex A - Review of a Possible Failure to Comply of the International Standard for Results Management .
5.4.4 The DCO /Chaperone may at their discretion consider any reasonable third-party request or any request by the Athlete for permission to delay reporting to the Doping Control Station following acknowledgment and acceptance of notification, and/or to leave the Doping Control Station temporarily after arrival.
The DCO /Chaperone may grant such permission if the Athlete can be continuously chaperoned and kept under continuous observation during the delay.
Delayed reporting to or temporary departure from the Doping Control Station may be permitted for the following activities: a) For In-Competition Testing: (i) Participation in a presentation ceremony; (ii) Fulfilment of media commitments; (iii) Competing in further Competitions ; (iv) Performing a warm down; (v) Obtaining necessary medical treatment; (vi) Locating a representative and/or interpreter; (vii) Obtaining photo identification; or (viii) Any other reasonable circumstances, as determined by the DCO , taking into account any ins tructions of the Testing Authority .
ISTI – Effective 1 January 2023 Page 45 of 92 b) For Out-of-Competition Testing: (i) Locating a representative; (ii) Completing a training session; (iii) Receiving necessary medical treatment; (iv) Obtaining photo identification; or (v) Any other reasonable circumstances, as determined by the DCO , taking into account any instructions of the Testing Authority .
5.4.5 A DCO /Chaperone shall reject a request for delay from an Athlete if it will not be possible for the Athlete to be continuously observed during such delay.
5.4.6 The DCO /Chaperone or other authorized Sample Collection Personnel shall document any reasons for delay in reporting to the Doping Control Station and/or reasons for leaving the Doping Control Station that may require further investigation by the Testing Authority .
5.4.7 If the Athlete delays reporting to the Doping Control S tation other than in accordance with Article 5.4.
4 and/or any failure of the Athlete to remain under constant observation during chaperoning but the Athlete arrives at the Doping Control Station prior to the DCO 's departure from the sample collection location, the DCO shall report a possible Failure to Comply .
If at all possible, the DCO shall proceed with collecting a Sample from the Athlete .
The Testing Authority shall investigate a possible Failure to Comply in accordance with Annex A - Review of a Possible Failure to Comply in the International Standard for Results Management .
5.4.8 If Sample Collection Personnel observe any other matter with potential to compromise the collection of the Sample, the circumstances shall be reported to and documented by the DCO .
If deemed appropriate by the DCO , the DCO shall consider if it is appropriate to collect an additional Sample from the Athlete.
The Testing Authority shall investigate a possible Failure to Comply in accordance with Annex A - Review of a Possible Failure to Comply in the International Standard for Results Management .
6.0 Preparing for the Sample Collection Session 6.1 Objective To prepare for the Sample Collection Session in a manner that ensures that the session can be conducted efficiently and effectively , including with sufficient resources e.g., personnel and equipment.
6.2 General Preparing for the Sample Collection Session starts with the establishment of a system for obtaining relevant information for effective conduct of the session and ends when it is confirmed that the Sample Collection Equipment conforms to the specified criteria.
The main activities are: ISTI – Effective 1 January 2023 Page 46 of 92 a) Establishing a system for collecting details regarding the Sample Collection Session; b) Establishing criteria for who may be present during a Sample Collection Session; c) Ensuring that the Doping Control Station meets the minimum criteria prescribed in Article 6.3.2; and d) Ensuring that the Sample Collection Equipment meets the minimum criteria prescribed in Article 6.3.4 .
6.3 Requirements for Preparing for Sample Collection Session 6.3.1 The Testing Authority , Doping Control Coordinator or Sample Collection Authority shall establish a system for obtaining all the information necessary to ensure that the Sample Collection Session can be conducted effectively, including identifying special requirements to meet the needs of Athletes with impairments (as provided in Annex A - Modifications for Athletes with Impairments) as well as t he needs of Athletes who are Minors (as provided in Annex B - Modifications for Athletes who are Minors ).
6.3.2 The DCO shall use a Doping Control Station which, at a minimum, ensures the Athlete's privacy and where possible is used solely as a Doping Control Station for the duration of the Sample Collection Session.
The DCO shall record any significant deviations from these criteria.
Should the DCO determine the Doping Control Station is unsuitable, they shall seek an alternative location which fulfils the minimum criteria above.
6.3.3 The Testing Authority or Sample Collection Authority shall establish criteria for who may be authorized to be present during the Sample Collection Session in addition to the Sample Collection Personnel .
At a minimum, the criteria shall include: a) An Athlete’s entitlement to be accompanied by a representative and/or interpreter during the Sample Collection Session, except when the Athlete is passing a urine Sample; b) The entitlement of an Athlete with an impairment to be accompanied by a representative as provided for in Annex A - Modifications for Athletes with Impairments; c) A Minor Athlete’s entitlement (as provided for in Annex B - Modifications for Athletes who are Minors ), and the witnessing DCO /Chaperone’s entitlement to have a representative observe the witnessing DCO /Chaperone when the Minor Athlete is passing a urine Sample, but without the representative directly observing the passing of the Sample unless requested to do so by the Minor Athlete; d) A WADA -appointed observer under the WADA Independent Observer Program or WADA auditor (where applicable); and/or e) An authorized Person who is involved in the training of Sample Collection Personnel or auditing the Sample Collection Authority .
ISTI – Effective 1 January 2023 Page 47 of 92 [Comment to 6.3.3 (d) and (e): The WADA observer/auditor and/or authorized Person shall not directly observe the passing of a urine Sample] 6.3.4 The Sample Collection Authority shall only use Sample Collection Equipment systems for urine and blood Samples which, at a minimum : a) Have a unique numbering system, incorporated into all A and B bottles, containers, tubes or other items used to seal the Sample and have a barcode or similar data code which meet s the requirements of ADAMS on the applicable Sample Collection Equipment ; b) Have a Tamper -Evident sealing system; c) Ensure the identity of the Athlete is not evident from the equipment itself; d) Ensure that all equipment is clean and sealed prior to use by the Athlete; e) Are constructed of a material and sealing system that is able to withstand the handling conditions and environment in which the equipment will be used or subjected to, including but not limited to transportation, Laboratory analysis and long term frozen storage up to the period of the statute of limitations; f) Are constructed of a material and sealing system that will; (i) Maintain the integrity (chemical and physical properties) of the Sa mple for the Analytical Testing; (ii) Can withstand temperatures of -80°C for urine and blood and -20°C for d ried blood spots.
Tests conducted to determine integrity under freezing conditions shall use the matrix or material that will be stored in the Sample bottles, containers or tubes i.e., urine, blood, or capillary blood applied on a dried blood spot absorbent Sample support (e.g., dried blood spot cellulose card or other equipment made of another material) ; (iii) Are constructed of a material and sealing system that can withstand a minimum of three (3) freeze/thaw cycles; g) The A and B bottles, containers and tubes shall be transpar ent so the Sample is visible; h) Have a sealing system which allows verification by the Athlete and the DCO that the Sample is correctly sealed in the A and B bottles or containers; i) Have a built -in security identification feature(s) which allows verification of the authenticity of the equipment; j) Are compliant with the standards published by the International Air Transport Association (IATA) for the transport of exempt human specimens which includes urine and/or blood Samples in order to prevent leakage during transportation by air or are compliant with the local and international regulations for the transport of dried blood spot Samples , if applicable; ISTI – Effective 1 January 2023 Page 48 of 92 k) Comply with local regulatory requirements for medical devices (for blood and dried blood spot Samples ) where necessary, as well as any other applicable law or regulation; l) Have been manufactured under the internationally recognized ISO 9001 certified standard which includes quality control management systems; m) Can be resealed after initial opening by a Laboratory using a new unique Tamper - Evident sealing system with a unique numbering system to maintain the integrity of the Sample and Chain of Custody in accordance with the requirements of the International Standard for Laboratories for long term storage of the Sample and Further Analysis ; n) Have undergone testing by a testing institution that is independent of the manufacturer and is ISO 17025 accredited, to validate at a minimum that the equipment meets the criteria set out in subsections b), f), g), h), i), j) and m) above; o) Any modification to the material or sealing system of the equipment shal l require re-testing to ensure it continues to meet the stated requirements as per n ) above; For Urine Sample Collection : p) Have the capacity to contain a minimum of 85 mL volume of urine in each A and B bottle or container; q) Have a visual marking on the A and B bottles or containers and the collection vessel, indicating: (i) the minimum volume of urine required in each A and B bottle or container as outlined in Annex C - Collection of Urine Samples ; (ii) the maximum volume levels that allow for expansion when frozen without compromising the bottle, container or the sealing system; and (iii) the level of Suitable Volume of Urine for Analysis on the collection vessel.
r) Include a partial Sample Tamper Evident sealing system with a unique numbering system to temporarily seal a Sample with an insufficient volume in accordance with Annex E - Urine Samples – Insufficient Volume; For Venous Blood Sample Collection : s) Have the ability to collect, store and transport blood in separate A and B tubes and containers; t) For the analysis of Prohibited Substances or Prohibited Methods in whole blood or plasma and/or for profiling blood parameters, the A and B tubes must have the capacity to contain a minimum of 3mL of blood and shall contain EDTA as an anti-coagulant; u) For the analysis of Prohibited Substances or Prohibited Methods in serum, the A ISTI – Effective 1 January 2023 Page 49 of 92 and B tubes must have the capacity to contain a minimum of 5mL of blood and shall contain an inert polymeric serum separator gel and clotting activation factor; and [Comment to 6.3.4 (t) and (u): If specific tubes have been indicated in the applicable WADA International Standard, Technical Document or Guidelines, then the use of alternative tubes which meet similar criter ia shall be validated with the involvement of the relevant Laboratory(ies) and approved by WADA prior to use for Sample collection.]
v) For the transport of blood Samples , ensure the storage and transport device and temperature data logger meet the requirements listed in Annex I - Collection, Storage and Transport of Blood Athlete Biological Passport Samples .
For Dried Blood Spot Sample Collection: w) A dried blood spot absorbent Sample support (e.g., dried blood spot cellulose card) shall also be labelled if it is necessary to remove it from its container at the Laboratory to take an aliquot ; and x) Allow the collection , storage and secure transportation of d ried blood spots on absorbent Sample support that can be sealed as distinct “A” and “B” Samples (Tamper Evident kit consisting of “A” and “B” containers/sub- containers and/or storage sleeves/packages/receptacles).
[Comment to 6.3.4 (x): Due to logistical reasons at the Laboratory , it is recommended to seal the “A” and “B” Samples in separate containers.
Transporting and/or storing “ A” and “B” Samples in the same container is however acceptable, provided that they are sealed as distinct “A” and “B” Samples.]
[Comment to 6.3.4: It is strongly recommended that prior to the equipment being made commercially available to stakeholders, s uch equipment be distributed to the anti -doping community, which may include Athletes, Testing Authorities , Sample Collection Authorities , Sample Collection Personnel , and Laboratories to seek feedback and ensure the equipment is fit for purpose.]
7.0 Conduct ing the Sample Collection Session 7.1 Objective To conduct the Sample Collection Session in a manner that ensures the integrity, identity and security of the Sample and respects the privacy and dignity of the Athlete.
7.2 General The Sample Collection Session starts with defining overall responsibility for the conduct of the Sample Collection Session and ends once the Sample has been collected and secured and the Sample collection documentation is complete.
The main activities are: a) Preparing for collecting the Sample ; ISTI – Effective 1 January 2023 Page 50 of 92 b) Collecting and securing the Sample; and c) Documenting the Sample collection.
7.3 Requirements Prior to Sample Collection 7.3.1 The Sample Collection Authority shall be responsible for the overall conduct of the Sample Collection Session, with specific responsibilities delegated to the DCO .
7.3.2 The DCO shall ensure that the Athlete has been informed of their rights and responsibilities as specified in Article 5.4.1.
7.3.3 The DCO /Chaperone shall advise the Athlete not to hydrate excessively, having in mind the requirement to provide a Sample with a Suitable Specific Gravity for Analysis .
7.3.4 The Anti-Doping Organization shall establish criteria regarding what items may be prohibited within the Doping Control Station .
At a minimum the se criteria shall prohibit the provision of alcohol or its consumption within the Doping Control Station .
7.3.5 The Athlete shall only leave the Doping Control Station under continuous observation by the DCO or Chaperone and with the approval of the DCO .
The DCO shall consider any reasonable request by the Athlete to leave the Doping Control Station , as specified in Articles 5.4.4, 5.4.5 and 5.4.6, until the Athlete is able to provide a Sample .
7.3.6 If the DCO gives approval for the Athlete to leave the Doping Control Station , the DCO shall agree with the Athlete on the following conditions of leave: a) The purpose of the Athlete leaving the Doping Control Station ; the time of return (or return upon completion of an agreed activity); b) That the Athlete must remain under continuous observation throughout; c) That the Athlete shall not pass urine until they arrive back at the Doping Control Station; and d) The DCO shall document the time of the Athlete’s departure and return.
7.4 Requirements for Sample Collection 7.4.1 The DCO shall collect the Sample from the Athlete according to the following protocol(s) for the specific type of Sample collection: a) Annex C - Collection of Urine Samples ; b) Annex D - Collection of Venous Blood Samples ; c) Annex I - Collection, Storage and Transport of B lood Athlete Biological Passport Samples ; d) Annex J - Collection, Storage and Transport of D ried Blood Spot Samples ; and ISTI – Effective 1 January 2023 Page 51 of 92 e) Annex K - Collection of Urine Samples in a Virtual Environment during a Pandemic .
7.4.2 Any behaviour by the Athlete and/or Persons associated with the Athlete or anomalies with potential to compromise the Sample collection shall be recorded in detail by the DCO .
If appropriate, the Testing Author ity shall apply Annex A - Review of a Possible Failure to Comply in the International Standard for Results Management .
7.4.3 If there are doubts as to the origin or authenticity of the Sample , the Athlete shall be asked to provide an additional Sample.
If the Athlete refuses to provide an additional Sample, the DCO shall document in detail the circumstances around the refusal, and the Testing Authority shall apply Annex A - Review of a Possible Failure to Comply in accordance with International Standard for Results Management .
7.4.4 The DCO shall provide the Athlete with the opportunity to document any concerns they may have about how the Sample Collection Session was conducted.
7.4.5 The following information shall be recorded as a minimum in relation to the Sample Collection Session: a) Date, time of notification, name and signature of notifying DCO /Chaperone; b) Arrival time of the Athlete at the Doping Control Station and any temporary departures and returns; c) Date and time of sealing of each Sample collected and date and time of completion of entire Sample collection process (i.e., the time when the Athlete signs the declaration at the bottom of the Doping Control form); d) The name of the Athlete; e) The date of bir th of the Athlete; f) The sport gender of the Athlete; g) Means by which the Athlete’s identity is validated (e.g., passport, driver’s license or Athlete accreditation) including by a third party (who is so identified); h) The Athlete 's home address, email address and telephone number; i) The Athlete’ s sport and discipline (in accordance with the TDSSA); j) The name of the Athlete ’s coach and doctor (if applicable); k) The Sample code number and reference to the equipment manufacturer , and where the Sample collected is d ried blood spot, detailed information on the model of the d ried blood spot Sample Collection Equipment (e.g., catalogue number) if the equipment manufacturer commercializes several d ried blood spot Sample collection kits ; l) The type of the Sample (urine, blood, d ried blood spot etc.
); ISTI – Effective 1 January 2023 Page 52 of 92 m) The type of Testing (In-Competition or Out-of-Competition ); n) The name and signature of the witnessing DCO /Chaperone; o) The name and signature of the BCO (where applicable); p) Partial Sample information, as per Annex E.4.4; q) Required Laboratory information on the Sample (i.e., for a urine Sample , its volume and specific gravity measurement) , as per Article 8.3.
3; r) Medications and supplements taken within the previous seven (7) days and (where the Sample collected is a blood Sample) blood transfusions within the previous three (3) months, as declared by the Athlete ; s) For a blood Athlete Biological Passport Sample, the DCO /BCO shall record the information as outlined in Annex I - Collection, Storage and Transport of Blood Athlete Biol ogical Passport Samples ; t) Any irregularities in procedures, for example, if advance notice was provided; u) Athlete comments or concerns regarding the conduct of the Sample Collection Session, as declared by the Athlete ; v) Athlete acknowledgment of the Processing of Sample collection data and description of such Processing in accordance with the International Standard for the Protection of Privacy and Personal Information; w) Athlete consent or otherwise for the use of the Sample(s) for research purposes; x) The name and signature of the Athlete ’s representative (if applicable), as per Article 7.4.6; y) The name and signature of the Athlete; z) The name and signature of the DCO ; aa) The name of the Testing Authority ; bb) The name of the Sample Collection Authority ; cc) The name of the Results Management Authority ; and dd) The name of the Doping Control Coordinator (if applicable).
[Comment to 7.4.5: All of the aforementioned information does not need to be consolidated in a singl e Doping Control form but rather may be collected during the Sample Collection Session and/or on other official documentation such as a separate notification form and/or supplementary report.]
7.4.6 At the conclusion of the Sample Collection Session, the Athlete and DCO shall sign appropriate documentation to indicate their satisfaction that the documentation ISTI – Effective 1 January 2023 Page 53 of 92 accurately reflects the details of the Athlete’s Sample Collection Session, including any concerns expressed by the Athlete.
The Athlete’s representative, if present and who witnessed the proceedings, should sign the documentation.
7.4.7 The Athle te shall be offered a copy of the records of the Sample Collection Session that have been signed by the Athlete whether electronically or otherwise.
8.0 Security/Post -Test Administration 8.1 Objective To ensure that all Samples collected at the Doping Control Station and Sample collection documentation are securely stored prior to transport from the Doping Control Station .
8.2 General Post-Test administration begins when the Athlete has left the Doping Control Station after providing their Sample(s) and ends with preparation of all of the collected Samples and Sample collection documentation for transport.